Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

FDA Approval of Eteplirsen for Muscular Dystrophy.

Sackner-Bernstein J.

JAMA. 2017 Apr 11;317(14):1480-1481. doi: 10.1001/jama.2017.2597. No abstract available.

PMID:
28399244
2.

Design of Hack-Resistant Diabetes Devices and Disclosure of Their Cyber Safety.

Sackner-Bernstein J.

J Diabetes Sci Technol. 2017 Mar;11(2):198-202. doi: 10.1177/1932296816678264. Epub 2016 Nov 11.

3.

Dietary Intervention for Overweight and Obese Adults: Comparison of Low-Carbohydrate and Low-Fat Diets. A Meta-Analysis.

Sackner-Bernstein J, Kanter D, Kaul S.

PLoS One. 2015 Oct 20;10(10):e0139817. doi: 10.1371/journal.pone.0139817. eCollection 2015.

4.

What is the greatest regulatory challenge in the translation of biomaterials to the clinic?

Prestwich GD, Bhatia S, Breuer CK, Dahl SL, Mason C, McFarland R, McQuillan DJ, Sackner-Bernstein J, Schox J, Tente WE, Trounson A.

Sci Transl Med. 2012 Nov 14;4(160):160cm14. doi: 10.1126/scitranslmed.3004915.

PMID:
23152323
5.

Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.

O'Connor CM, Miller AB, Blair JE, Konstam MA, Wedge P, Bahit MC, Carson P, Haass M, Hauptman PJ, Metra M, Oren RM, Patten R, PiƱa I, Roth S, Sackner-Bernstein JD, Traver B, Cook T, Gheorghiade M; Efficacy of Vasopressin Antagonism in heart Failure Outcome Study with Tolvaptan (EVEREST) investigators.

Am Heart J. 2010 May;159(5):841-849.e1. doi: 10.1016/j.ahj.2010.02.023. Erratum in: Am Heart J. 2012 May;163(5):900.

PMID:
20435194
6.

Mechanisms underlying improvements in ejection fraction with carvedilol in heart failure.

Maurer MS, Sackner-Bernstein JD, El-Khoury Rumbarger L, Yushak M, King DL, Burkhoff D.

Circ Heart Fail. 2009 May;2(3):189-96. doi: 10.1161/CIRCHEARTFAILURE.108.806240. Epub 2009 Apr 14.

PMID:
19808339
7.

Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) Trial.

Udelson JE, Pressler SJ, Sackner-Bernstein J, Massaro J, Ordronneau P, Lukas MA, Hauptman PJ.

J Card Fail. 2009 Jun;15(5):385-93. doi: 10.1016/j.cardfail.2008.12.010. Epub 2009 Feb 12.

PMID:
19477398
8.

Role of beta-blocker therapy in the postmyocardial infarction patient with and without left ventricular dysfunction consensus guideline.

Fonarow GC, Abraham WT, Gheorghiade M, Cannon CP, Sackner-Bernstein JD, Udelson JE, Konstam MA; Postmyocardial Infarction Consensus Guideline Committee.

Crit Pathw Cardiol. 2003 Dec;2(4):239-46. doi: 10.1097/01.hpc.0000099743.53432.a8. No abstract available.

PMID:
18340127
9.

Nesiritide for acute decompensated heart failure: does the benefit justify the risk?

Sackner-Bernstein J, Aaronson KD.

Curr Cardiol Rep. 2007 May;9(3):187-93. Review.

PMID:
17470331
10.

Rationale and design of CASPER: compliance and quality of life study comparing once-daily carvedilol CR and twice-daily carvedilol IR in patients with heart failure.

Hauptman PJ, Pressler SJ, Sackner-Bernstein J, Ordronneau P, Udelson JE; CASPER Investigators.

Am J Cardiol. 2006 Oct 2;98(7A):60L-66L. Epub 2006 Aug 28.

PMID:
17023234
11.

Risk of death associated with nesiritide in patients with acutely decompensated heart failure.

Aaronson KD, Sackner-Bernstein J.

JAMA. 2006 Sep 27;296(12):1465-6. No abstract available.

PMID:
17003394
12.
13.

Nesiritide--not verified.

Sackner-Bernstein J, Aaronson KD.

N Engl J Med. 2005 Oct 6;353(14):1525-7; author reply 1525-7. No abstract available.

PMID:
16207860
14.

Management of diuretic-refractory, volume-overloaded patients with acutely decompensated heart failure.

Sackner-Bernstein JD.

Curr Cardiol Rep. 2005 May;7(3):204-10. Review.

PMID:
15865862
15.
16.

Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure.

Sackner-Bernstein JD, Skopicki HA, Aaronson KD.

Circulation. 2005 Mar 29;111(12):1487-91. Epub 2005 Mar 21. Erratum in: Circulation. 2005 May 3;111(17):2274.

PMID:
15781736
17.
18.

Eprosartan improves cardiac performance, reduces cardiac hypertrophy and mortality and downregulates myocardial monocyte chemoattractant protein-1 and inflammation in hypertensive heart disease.

Behr TM, Willette RN, Coatney RW, Berova M, Angermann CE, Anderson K, Sackner-Bernstein JD, Barone FC.

J Hypertens. 2004 Mar;22(3):583-92.

PMID:
15076165
19.

Neurohormonal antagonism in heart failure: what is the optimal strategy?

Sackner-Bernstein JD, Hart D.

Mt Sinai J Med. 2004 Mar;71(2):115-26. Review.

PMID:
15029403
20.

What is the role of biventricular pacing the transplant candidate?

Sackner-Bernstein J, Farmer DM.

Coron Artery Dis. 2004 Mar;15(2):81-5. Review. No abstract available.

PMID:
15024294
21.

Racing away from bias.

Sackner-Bernstein JD, Skopicki HA.

J Am Coll Cardiol. 2004 Mar 3;43(5):785-6. No abstract available.

22.

Increasing organ transplantation--fairly.

Sackner-Bernstein JD, Godin S.

Transplantation. 2004 Jan 15;77(1):157-9.

PMID:
14724457
23.

Role of beta-blocker therapy in the post-myocardial infarction patient with and without left ventricular dysfunction.

Fonarow GC, Abraham WT, Cannon CP, Gheorghiade M, Sackner-Bernstein JD, Udelson JE; Post-Myocardial Infarction Guideline Committee.

Rev Cardiovasc Med. 2003;4 Suppl 3:S54-9. Review. No abstract available.

PMID:
14584479
24.

New evidence from the CAPRICORN Trial: the role of carvedilol in high-risk, post-myocardial infarction patients.

Sackner-Bernstein JD.

Rev Cardiovasc Med. 2003;4 Suppl 3:S25-9. Review.

PMID:
14564231
25.

How should diuretic-refractory, volume-overloaded heart failure patients be managed?

Sackner-Bernstein JD, Obeleniene R.

J Invasive Cardiol. 2003 Oct;15(10):585-90. Review.

PMID:
14519893
26.

The JNC 7 hypertension guidelines.

Sackner-Bernstein J.

JAMA. 2003 Sep 10;290(10):1312; author reply 1314-5. No abstract available.

PMID:
12966114
27.

New concepts in the clinical aspects of cardiovascular disease.

Goldberg N, Sackner-Bernstein J, DePuey G.

AIDS Read. 2003 Apr;13(4 Suppl):S25-9. Review.

PMID:
12762291
28.

Robotically assisted left ventricular epicardial lead implantation for biventricular pacing.

DeRose JJ, Ashton RC, Belsley S, Swistel DG, Vloka M, Ehlert F, Shaw R, Sackner-Bernstein J, Hillel Z, Steinberg JS.

J Am Coll Cardiol. 2003 Apr 16;41(8):1414-9.

30.

Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunction.

Behr TM, Nerurkar SS, Nelson AH, Coatney RW, Woods TN, Sulpizio A, Chandra S, Brooks DP, Kumar S, Lee JC, Ohlstein EH, Angermann CE, Adams JL, Sisko J, Sackner-Bernstein JD, Willette RN.

Circulation. 2001 Sep 11;104(11):1292-8.

PMID:
11551882
31.

The myocardial matrix and the development and progression of ventricular remodeling.

Sackner-Bernstein JD.

Curr Cardiol Rep. 2000 Mar;2(2):112-9. Review.

PMID:
10980881
32.

Use of carvedilol in chronic heart failure: challenges in therapeutic management.

Sackner-Bernstein JD.

Prog Cardiovasc Dis. 1998 Jul-Aug;41(1 Suppl 1):53-8. Review.

PMID:
9715823
33.

Long-term carvedilol therapy increases parasympathetic nervous system activity in chronic congestive heart failure.

Goldsmith RL, Bigger JT, Bloomfield DM, Krum H, Steinman RC, Sackner-Bernstein J, Packer M.

Am J Cardiol. 1997 Oct 15;80(8):1101-4.

PMID:
9352991
34.

Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group.

Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackner-Bernstein JD, Young ST, Holcslaw TL, Lukas MA.

Circulation. 1996 Dec 1;94(11):2800-6.

PMID:
8941105
35.

Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise.

Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D, Cody RJ, Gregory JJ, Kantrowitz NE, LeJemtel TH, Young ST, Lukas MA, Shusterman NH.

Circulation. 1996 Dec 1;94(11):2793-9.

PMID:
8941104
36.

Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure.

Krum H, Gu A, Wilshire-Clement M, Sackner-Bernstein J, Goldsmith R, Medina N, Yushak M, Miller M, Packer M.

Am Heart J. 1996 Feb;131(2):337-41.

PMID:
8579030
37.

Rationale for treatment of patients with chronic heart failure with adrenergic blockade.

Sackner-Bernstein JD, Mancini DM.

JAMA. 1995 Nov 8;274(18):1462-7. Review. Erratum in: JAMA 1996 Mar 6;275(9):686.

PMID:
7474194
38.

Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure.

Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, Medina N, Yushak M, Horn E, Katz SD, et al.

Circulation. 1995 Sep 15;92(6):1499-506.

PMID:
7664433

Supplemental Content

Loading ...
Support Center